Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) Other Stockholders Equity: HK$689.1 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02591 Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
8 GF Score
Price HK$3.87
! 3 Warning Signs
View Full Analysis

What is Guangzhou Innogen Pharmaceutical Group Co Other Stockholders Equity?

Guangzhou Innogen Pharmaceutical Group Co HKSE:02591 -3.73% 8 Other Stockholders Equity is HK$689.1 Mil as of Dec. 2025. GuruFocus rates HKSE:02591 with a GF Score™ of 8/100. The stock has 3 warning signs investors should review.

Guangzhou Innogen Pharmaceutical Group Co's Other Stockholders Equity for the quarter that ended in Dec. 2025 was HK$689.1 Mil.

Guangzhou Innogen Pharmaceutical Group Co's quarterly Other Stockholders Equity increased from Dec. 2024 (HK$650.5 Mil) to Jun. 2025 (HK$675.5 Mil) and increased from Jun. 2025 (HK$675.5 Mil) to Dec. 2025 (HK$689.1 Mil).

Guangzhou Innogen Pharmaceutical Group Co's annual Other Stockholders Equity increased from Dec. 2023 (HK$648.9 Mil) to Dec. 2024 (HK$650.5 Mil) and increased from Dec. 2024 (HK$650.5 Mil) to Dec. 2025 (HK$689.1 Mil).

Guangzhou Innogen Pharmaceutical Group Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Guangzhou Innogen Pharmaceutical Group Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Innogen Pharmaceutical Group Co Other Stockholders Equity Chart

Guangzhou Innogen Pharmaceutical Group Co Annual Data
Trend Dec23 Dec24 Dec25
Other Stockholders Equity
648.87 650.51 689.13

Guangzhou Innogen Pharmaceutical Group Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity 648.87 0.00 650.51 675.50 689.13
HKSE:02591
8GF Score
Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Innogen Pharmaceutical Group Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of HK$689.1 Mil mean?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a Other Stockholders Equity of HK$689.1 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors.
Is Guangzhou Innogen Pharmaceutical Group Co's Other Stockholders Equity too high?
Guangzhou Innogen Pharmaceutical Group Co's current Other Stockholders Equity is HK$689.1 Mil. Overall, Guangzhou Innogen Pharmaceutical Group Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Innogen Pharmaceutical Group Co's Other Stockholders Equity compare to VRTX and REGN?
Guangzhou Innogen Pharmaceutical Group Co's Other Stockholders Equity of HK$689.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. Guangzhou Innogen Pharmaceutical Group Co's current Other Stockholders Equity is HK$689.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Innogen Pharmaceutical Group Co stock overvalued right now?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a current Other Stockholders Equity of HK$689.1 Mil. The current Other Stockholders Equity is HK$689.1 Mil. Guangzhou Innogen Pharmaceutical Group Co's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591), the current Other Stockholders Equity is HK$689.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Guangzhou Innogen Pharmaceutical Group Co Business Description

Address No. 2 Tengfei Second Street, Room 409, Building H Self-numbered Creative Building, China-Singapore Guangzhou Knowledge City, Huangpu District, Guangdong Province, Guangzhou, CHN
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
8GF Score

Get the complete analysis for HKSE:02591

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.87
Price